American Association for Cancer Research
Browse
can-22-2350_supplementary_figure_s5_part_2_suppsf5-2.pdf (763.4 kB)

Supplementary Figure S5 Part 2 from CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma

Download (763.4 kB)
journal contribution
posted on 2023-12-01, 08:22 authored by Karen L. Burger, Mario R. Fernandez, Mark B. Meads, Praneeth Sudalagunta, Paula S. Oliveira, Rafael Renatino Canevarolo, Raghunandan Reddy Alugubelli, Alexandre Tungsevik, Gabe De Avila, Maria Silva, Allison I. Graeter, Hongyue A. Dai, Nicole D. Vincelette, Antony Prabhu, Dario Magaletti, Chunying Yang, Weimin Li, Amit Kulkarni, Oliver Hampton, John M. Koomen, William R. Roush, Andrii Monastyrskyi, Anders E. Berglund, Ariosto S. Silva, John L. Cleveland, Kenneth H. Shain

Figure S5 Part 2

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

History

ARTICLE ABSTRACT

Multiple myeloma remains an incurable malignancy due to acquisition of intrinsic programs that drive therapy resistance. Here we report that casein kinase-1δ (CK1δ) and CK1ε are therapeutic targets in multiple myeloma that are necessary to sustain mitochondrial metabolism. Specifically, the dual CK1δ/CK1ε inhibitor SR-3029 had potent in vivo and ex vivo anti–multiple myeloma activity, including against primary multiple myeloma patient specimens. RNA sequencing (RNA-seq) and metabolic analyses revealed inhibiting CK1δ/CK1ε disables multiple myeloma metabolism by suppressing genes involved in oxidative phosphorylation (OxPhos), reducing citric acid cycle intermediates, and suppressing complexes I and IV of the electron transport chain. Finally, sensitivity of multiple myeloma patient specimens to SR-3029 correlated with elevated expression of mitochondrial genes, and RNA-seq from 687 multiple myeloma patient samples revealed that increased CSNK1D, CSNK1E, and OxPhos genes correlate with disease progression and inferior outcomes. Thus, increases in mitochondrial metabolism are a hallmark of multiple myeloma progression that can be disabled by targeting CK1δ/CK1ε. CK1δ and CK1ε are attractive therapeutic targets in multiple myeloma whose expression increases with disease progression and connote poor outcomes, and that are necessary to sustain expression of genes directing OxPhos.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC